New Delhi, 14 February 2025: Orchid Pharma Ltd., a vertically integrated pharmaceutical company spanning the entire pharmaceutical value chain from discovery to delivery has announced its Q3 financial results for FY 2024-25, reporting a 26% year-on-year increase in Profit After Tax (PAT) in YoY-9 month. This steady trajectory reflects the company’s strategic execution and ongoing expansion efforts, particularly in the Anti-Microbial Stewardship (AMS) division, which…